MedTrace Logo

HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome

NCT04591990 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2025-06-12

No results posted yet for this study

Summary

The primary objective is to demonstrate the superiority of arginine-vasopressin (AVP) and hydrocortisone compared with norepinephrine regarding day-30 survival and neurological recovery in post-cardiac arrest patients with hemodynamic failure.

Conditions

  • Postresuscitation Syndrome

Interventions

DRUG

Administration of AVP

Administration of AVP

DRUG

Administration of placebo AVP

Administration of placebo AVP

DRUG

Administration of placebo hydrocortisone

Administration of placebo hydrocortisone

DRUG

Administration of hydrocortisone

Administration of hydrocortisone

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Guillaume GERI, MD, PhD · Intensive Care Unit, Clinique Ambroise Paré, 92200 Neuilly sur seine

  • Alain CARIOU, MD, PhD · Medical Intensive Care Unit, Cochin Hospital, APHP, 75014 Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-27
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04591990 on ClinicalTrials.gov